Mechanistic description
The dopaminergic ventral tegmental-striatal circuit protection hypothesis proposes that MAPT-encoded tau protein dysfunction specifically compromises dopaminergic neurotransmission through disrupted axonal transport and synaptic vesicle dynamics. Under normal conditions, tau protein facilitates the transport of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and vesicular monoamine transporter 2 (VMAT2) along dopaminergic axons projecting from the ventral tegmental area to the nucleus accumbens and dorsal striatum. Hyperphosphorylated tau at critical residues (Ser202/Thr205, Ser396/Ser404) mediated by GSK-3β and CDK5 disrupts microtubule stability, leading to impaired anterograde transport of dopamine synthesis machinery and synaptic vesicles. This results in reduced dopamine production at synaptic terminals and compromised vesicular packaging. Dopaminergic neurons are particularly vulnerable due to their extensive axonal arborization spanning long distances and their high metabolic demands for dopamine synthesis and vesicular transport. The disrupted tau function impairs the delivery of dopamine D1 and D2 receptor signaling components while reducing retrograde transport of neurotrophic factors including glial cell line-derived neurotrophic factor (GDNF) and its receptor GFRα1. This leads to diminished activation of the RET receptor tyrosine kinase and downstream PI3K/Akt survival pathways. The resulting synaptic dysfunction manifests as reduced dopamine release, impaired D1 receptor-mediated cAMP/protein kinase A signaling in medium spiny neurons, and disrupted striatal gamma oscillations critical for motor learning and cognitive flexibility. This mechanism provides a novel framework for understanding how tau pathology contributes to motor and cognitive symptoms through dopaminergic circuit dysfunction rather than cholinergic impairment.
Evidence for (13)
Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seeding mouse model of Alzheimer's disease, suggesting this pathway is critical for circuit maintenance
Hippocampal interneurons shape spatial coding alterations in neurological disorders
TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration.
Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies.
Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus.
Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17.
Spontaneous tauopathy with parkinsonism in an aged cynomolgus macaque.
Progressive Supranuclear Palsy-A Global Review.
Alzheimer's disease basics: we all should know.
Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.
NAD(+) restores proteostasis through splicing-dependent autophagy.
A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.
Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.
Evidence against (4)
CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.
Viral and non-viral cellular therapies for neurodegeneration.
Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights.
Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders.
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund
signals from 2 contributing personas in
log-odds space, weighted by uniform.
Prior 50%.